Richter transformation acquiring <i>PLCG2</i> mutation during Bruton tyrosine kinase inhibitors treatment-Reference-Cited by-同舟云学术

Richter transformation acquiring PLCG2 mutation during Bruton tyrosine kinase inhibitors treatment

Published:2024-04-14 Issue:3 Volume:5 Page:642-645
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Tsushima Takafumi¹²^ORCID,Sato Nobue³,Guo Yong‐Mei¹,Nakamura Hirotaka¹,Kunisada Kodai¹,Chi Song‐Gi¹,Akie Kenta⁴,Takahashi Yuki⁴,Nakamura Saki⁴,Shimada Kaoru⁵,Ishii Genichiro⁶,Minami Yosuke¹^ORCID,Yuda Junichiro¹^ORCID

Affiliation:

1. Department of Hematology and Oncology National Cancer Center Hospital East Kashiwa Japan

2. Department of Hematology and Oncology Japanese Red Cross Narita Hospital Narita Japan

3. Pharmaceutical Department National Cancer Center Hospital East Kashiwa Japan

4. Department of Clinical Laboratories National Cancer Center Hospital East Kashiwa Japan

5. Department of Radiology National Cancer Center Hospital East Kashiwa Japan

6. Department of Pathology National Cancer Center Hospital East Kashiwa Japan

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.891

Reference14 articles.

1. Biology and Treatment of Richter Transformation

2. Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase

3. Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study

4. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial

5. Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ibrutinib;Reactions Weekly;2024-08-31